New hope for stubborn lung disease when first treatments fail
NCT ID NCT02990286
Summary
This study tested whether adding the drug rituximab to standard mycophenolate treatment helps adults with progressive interstitial lung disease (ILD) who didn't improve on their first immunosuppressive therapy. The goal was to see if this combination could better preserve lung function and slow disease progression over six months compared to using mycophenolate alone. Researchers measured breathing capacity, quality of life, and safety in 122 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASE, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM Hôpital NORD
Marseille, 13015, France
-
CHRU Tours
Tours, 37044, France
-
Chu Besancon
Besançon, 25030, France
-
Chu Dijon
Dijon, 21079, France
-
Chu Rennes
Rennes, 35033, France
Conditions
Explore the condition pages connected to this study.